Article -> Article Details
|Title||Preimplantation Genetic Testing Market To Show Detail Growth Prospects and Strategies by 2031|
|Category||Fitness Health --> News & Media|
|Meta Keywords||Preimplantation Genetic Testing Market, Preimplantation Genetic Testing Market report, Preimplantation Genetic Testing industry, Preimplantation Genetic Testing Market size, Preimplantation Genetic Testing Market value , Preimplantation Genetic Testing Market growth|
The preimplantation genetic testing is set to grow at a significant rate in the upcoming years as the technology and awareness regarding the test improve.
Preimplantation genetic diagnosis (PGD) is performed among couples that have a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates. The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.
The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.
The growth is attributed to the advancing maternal age globally, rising adoption of in-vitro fertilization, increasing awareness of genetic testing, and rising emphasis on predictive testing. Further, continued significant investments by biotechnology firms to improve the technology for genetic testing and to improve affordability have also promoted the prominence of preimplantation genetic testing.
The exponential rise in the usage of in-vitro fertilization facilities as an option for healthy childbirth and increasing affordability for genetic testing on a global level has created awareness as well as demand among consumers, which has eventually led to the companies to invest in the development of more such preimplantation genetic test. The companies such as Agilent Technologies, Inc. and Natera, Inc. have been incorporating major strategies to enhance their market presence via key developments. The other major contributors to the market include companies such as Thermo Fisher Scientific, PerkinElmer, Inc., Invitae Inc., and Igenomix.
Based on region, North America holds the largest share of the preimplantation genetic testing market due to eased regulatory scenario and a large number of IVF facilities offering such PGT tests. Further, substantial investments made by biotechnology companies to improve the genetic testing facilities and advancing technologies along with the rise in per capita income in the region are also fueling the growth of the respective market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Preimplantation Genetic Testing Market Dynamics
Key Companies Profiled
Abbott Laboratories, Agilent Technologies, Inc., BGI, Fulgent Genetics, Inc., Igenomix, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., MedGenome Labs Ltd., Natera, Inc., PerkinElmer, Inc., Pac Genomics, Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
• What are the factors necessitating the requirement of global preimplantation genetic testing globally?
Get Free Sample Report- https://bisresearch.com/requestsample?id=1211type=download
BIS Related Studies